Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Senores Pharmaceuticals Ltd. (SENORES) Stock Price & Analysis

1 Followers

SENORES Stock Chart & Stats

₹1,171.95-₹3.95(-0.34%)
At close: 3:30 PM GMT+5:30
₹1.25K₹1.5KAug 17Aug 31Sep 15Sep 28Oct 12Oct 26Nov 9
Day’s Range
INR 1,161.00 - INR 1,187.40
52-Week Range
INR 708.10 - INR 1,599.55
Previous Close
INR 1,175.90
Volume
N/A
Average Volume (3M)
14.80K
Market Cap
INR 54.15B
Enterprise Value
INR 67.20B
Total Cash (Recent Filing)
INR 3.60B
Total Debt (Recent Filing)
INR 2.41B
Price to Earnings (P/E)
38.5
Beta
0.73
Next Earnings
Jan 28, 2027 (Est.)
EPS Estimate
8.8
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

FY2026 Scale And Margins

Revenue expanded about 151% to 6.33B in FY2026 while gross, EBIT and net margins reached approximately 60%, 29% and 18%. This combination indicates materially greater operating scale and current earnings capacity, providing a stronger base for reinvestment over the next several quarters.

Moderate Leverage

Debt-to-equity improved from roughly 0.40 to 0.37 as equity rose to 9.34B. This indicates moderate leverage rather than an overextended capital structure, giving the company some balance-sheet capacity to support operations while preserving more flexibility than a highly levered peer.

Revenue Growth

The reported 39.7% revenue growth rate supports a durable expansion narrative beyond the single-year income statement jump. Continued top-line growth can broaden the revenue base, improve operating scale, and support sustained investment in the company's pharmaceutical business if profitability holds.

Bears Say

Persistent Negative Free Cash Flow

Free cash flow remained about -2.03B in both FY2025 and FY2026 despite the latest profit improvement. Persistent cash outflow means reported earnings are not translating into internally generated funds, increasing the need to finance investment or working-capital demands externally.

Profitability Volatility

Results are highly uneven across the two reported years: FY2026 delivered roughly 60% gross and 18% net margins, while FY2025 profitability was described as extremely weak. Such volatility reduces confidence that current margins represent a stable earnings base over the next several quarters.

Meaningful Debt Burden

Total debt was still 3.42B in FY2026, even after debt-to-equity improved to about 0.37. The remaining obligation is meaningful alongside deeply negative free cash flow, potentially limiting financial flexibility and increasing reliance on successful cash generation to fund the business.

Senores Pharmaceuticals Ltd. News

SENORES FAQ

What was Senores Pharmaceuticals Ltd.’s price range in the past 12 months?
Senores Pharmaceuticals Ltd. lowest stock price was ₹708.10 and its highest was ₹1599.55 in the past 12 months.
What is Senores Pharmaceuticals Ltd.’s market cap?
Senores Pharmaceuticals Ltd.’s market cap is ₹54.15B.
When is Senores Pharmaceuticals Ltd.’s upcoming earnings report date?
Senores Pharmaceuticals Ltd.’s next earnings report is estimated for Jan 28, 2027 (not yet confirmed), which is in 76 days.
How were Senores Pharmaceuticals Ltd.’s earnings last quarter?
Senores Pharmaceuticals Ltd. released its earnings results on Oct 29, 2026. The company reported ₹8.6 earnings per share for the quarter, beating the consensus estimate of ₹8.25 by ₹0.35.
Is Senores Pharmaceuticals Ltd. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Senores Pharmaceuticals Ltd. pay dividends?
Senores Pharmaceuticals Ltd. does not currently pay dividends.
What is Senores Pharmaceuticals Ltd.’s EPS estimate?
Senores Pharmaceuticals Ltd.’s EPS estimate is 8.80.
How many shares outstanding does Senores Pharmaceuticals Ltd. have?
Senores Pharmaceuticals Ltd. has 46,053,590 shares outstanding.
What happened to Senores Pharmaceuticals Ltd.’s price movement after its last earnings report?
Senores Pharmaceuticals Ltd. reported an EPS of ₹8.6 in its last earnings report, beating expectations of ₹8.25. Following the earnings report the stock price went down -7.968%.
Which hedge fund is a major shareholder of Senores Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in IN:SENORES
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology